Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmHrpmIrpmJrpmJ2rpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsU
The experimentally established mechanism targets of Tobramycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.73 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | GJB2 | P29033 | 6/20 | 0.63 |
| ▸ | GJA1 | P17302 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tobramycin SCHEMBL316999 | 1.00 | ALOX15 (0.73) | ALOX15HPSECYP3A4GAAGJB2 | |
| Tobramycin SCHEMBL2526940 | 1.00 | ALOX15 (0.73) | ALOX15HPSECYP3A4GAAGJB2 | |
| Tobramycin SCHEMBL1177718 | 1.00 | ALOX15 (0.73) | ALOX15HPSECYP3A4GAAGJB2 | |
| Tobramycin SCHEMBL2478754 | 1.00 | ALOX15 (0.73) | ALOX15HPSECYP3A4GAAGJB2 | |
| Tobramycin SCHEMBL317114 | 1.00 | ALOX15 (0.73) | ALOX15HPSECYP3A4GAAGJB2 | |
| Tobramycin SCHEMBL22722916 | 0.91 | ALOX15 (0.71) | ALOX15HPSECYP3A4GAAGJB2 | |
| Tobramycin SCHEMBL1178021 | 0.88 | ALOX15 (0.87) | ALOX15HPSECYP3A4GAAGJB2 | |
| Tobramycin SCHEMBL6439170 | 0.87 | GAA (0.78) | ALOX15HPSECYP3A4GAAGJB2 | |
| Tobramycin SCHEMBL17496961 | 0.87 | ALOX15 (0.89) | ALOX15HPSECYP3A4GAAGJB2 | |
| Tobramycin SCHEMBL3658310 | 0.86 | ALOX15 (1.00) | ALOX15HPSECYP3A4GAAGJB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2529763-B1 | Method for manufacturing an implant coating and implant | LINK WALDEMAR GMBH CO (DE) | 2016-10-12 | — | — | EP | claimed |
| US-20070264304-A1 | PROVISION OF VASCULAR GRAFTS WITH AN ACTIVE PRINCIPLE | HERAEUS KULZER GMBH (DE) | 2007-11-15 | — | — | US | claimed |
| EP-1374923-B1 | Porous implants with antibiotic coating, their preparation and use | HERAEUS KULZER GMBH (DE) | 2006-08-30 | — | — | EP | claimed |
| US-7030093-B2 | Antibiotic coating for porous bodies and method for its production as well as its use | HERAEUS KULZER GMBH & CO. KG (DE) | 2006-04-18 | — | — | US | claimed |
| EP-1398046-B1 | Antibioticum-/Antibiotica-polymer composite | HERAEUS KULZER GMBH (DE) | 2005-07-27 | — | — | EP | claimed |
| US-20040137065-A1 | Antibiotic polymer combination/antibiotics polymer combination | HERAEUS KULZER GMBH & CO. KG (DE) | 2004-07-15 | — | — | US | claimed |
| US-20040048786-A1 | Antibiotic coating for porous bodies and method for its production as well as its use | HERAEUS KULZER GMBH & CO.KG (DE) | 2004-03-11 | — | — | US | claimed |
| US-20140099353-A1 | METHOD FOR PRODUCING AN IMPLANT COATING, AND CORRESPONDING IMPLANT | DERU GMBH (DE) | 2014-04-10 | — | — | US | disclosed |
| CN-101049520-B | Preparing blood vessel graft containing active components | HERAEUS KULZER GMBH | 2011-11-09 | — | — | CN | disclosed |
| US-20080221049-A1 | Free-flowing lyophilized tobramycin formulation | APP PHARMACEUTICALS, LLC. (US) | 2008-09-11 | — | — | US | disclosed |
| US-20070264304-A1 | PROVISION OF VASCULAR GRAFTS WITH AN ACTIVE PRINCIPLE | HERAEUS KULZER GMBH (DE) | 2007-11-15 | — | — | US | disclosed |
| US-20070264304-A1 | PROVISION OF VASCULAR GRAFTS WITH AN ACTIVE PRINCIPLE | HERAEUS KULZER GMBH (DE) | 2007-11-15 | — | — | US | disclosed |
| JP-2007275598-A | MANUFACTURE OF VASCULAR GRAFT WITH ACTIVE PRINCIPLE | HERAEUS KULZER GMBH | 2007-10-25 | — | — | JP | disclosed |
| CN-1310682-C | Antibiotic coating of porous body, its prepn. and application | HOLISH GUSSA GMBH & CO KG (DE) | 2007-04-18 | — | — | CN | disclosed |
| US-7030093-B2 | Antibiotic coating for porous bodies and method for its production as well as its use | HERAEUS KULZER GMBH & CO. KG (DE) | 2006-04-18 | — | — | US | disclosed |
| US-7030093-B2 | Antibiotic coating for porous bodies and method for its production as well as its use | HERAEUS KULZER GMBH & CO. KG (DE) | 2006-04-18 | — | — | US | disclosed |
| US-20040137065-A1 | Antibiotic polymer combination/antibiotics polymer combination | HERAEUS KULZER GMBH & CO. KG (DE) | 2004-07-15 | — | — | US | disclosed |
| US-20040048786-A1 | Antibiotic coating for porous bodies and method for its production as well as its use | HERAEUS KULZER GMBH & CO.KG (DE) | 2004-03-11 | — | — | US | disclosed |
| US-20040048786-A1 | Antibiotic coating for porous bodies and method for its production as well as its use | HERAEUS KULZER GMBH & CO.KG (DE) | 2004-03-11 | — | — | US | disclosed |
| CN-1480226-A | Antibiotic coating of porous body, its prepn. and application | — | 2004-03-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221049-A1 | Free-flowing lyophilized tobramycin formulation | TNF, CFTR, TREH | ALOX15 2551/4885HPSE 3382/4885CYP3A4 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.